| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
10% Owner | Former 10% Owner
6 companies
Boxer Capital, LLC last filed a Form 4 in February 2024, as 10% Owner at TNGX. The filings on record cover 6 companies.
Our model assigns Boxer Capital, LLC a strong insider score of 79/100, based on 12 past trades. Over a 12-month horizon, 75.0% of those trades were profitable, with an average 12-month return of +39.4%.
At the last filing, the largest reported position was 8,198,642 shares of TNGX. Net of sales, the TNGX filings show accumulation of 1,919,000 shares.
Boxer Capital, LLC has 12 Form 4 filings on record from June 2016 to February 2024, across 6 companies: Tyra Biosciences (TYRA), 2021–2024; Tango Therapeutics (TNGX), 2022–2023; Former 10% Owner at PMV Pharmaceuticals (PMVP), 2020, and 3 more.
The 37 reported transactions were 15 open-market sales, 14 open-market purchases, 6 conversions and 1 stock award, plus smaller numbers of other types.
Counted by filing, the open-market trades come to 7 purchases worth about $41.7M and 4 sales worth about $15.2M.
The largest open-market purchase was 950,000 shares of PMVP at an average $18.00 on September 25, 2020, about $17.1M.
The largest open-market sale was 100,000 shares of ESPR at an average $56.38 on November 5, 2018, about $5.6M.
Shares as reported in the last Form 4 for each company; the most recent is from February 2024. Values use today's prices. Any trades after the last filing were not reported, so current holdings may differ.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Oct 16, 2023 | TNGX Tango Therapeutics, Inc. | - | Buy10b5-1 | 1,250,000 | $6.98 | $8,722,500.00 | +18.0% | +62.0% | +6.0% | |
| Oct 9, 2023 | TNGX Tango Therapeutics, Inc. | - | Sell | 225,000 | $9.96 | $2,240,250.00 | -3.1% | -4.1% | -30.2% | |
| Aug 11, 2023 | TNGX Tango Therapeutics, Inc. | - | Buy | 475,000 | $5.15 | $2,446,250.00 | +176.9% | +11.9% | +13.2% | |
| Oct 13, 2022 | TNGX Tango Therapeutics, Inc. | 10% Owner | Buy | 237,000 | $4.41 | $1,044,573.30 | +3.4% | +66.2% | +62.6% | |
| Oct 6, 2022 | TNGX Tango Therapeutics, Inc. | 10% Owner | Buy | 182,000 | $3.92 | $714,096.47 | +2.6% | +87.8% | +176.9% | |
| Dec 17, 2021 | TYRA Tyra Biosciences, Inc. | 10% Owner | Buy | 125,000 | $13.12 | $1,640,312.50 | +2.0% | -3.6% | -44.0% | |
| Sep 17, 2021 | TYRA Tyra Biosciences, Inc. | 10% Owner | Buy | 625,000 | $16.00 | $10,000,000.00 | +11.0% | -31.0% | -61.1% | |
| Sep 25, 2020 | PMVP Pmv Pharmaceuticals, Inc. | Former 10% Owner | Buy | 950,000 | $18.00 | $17,100,000.00 | New | - | - | |
| Mar 28, 2019 | SLDB Solid Biosciences Inc. | 10% Owner | Sell | 450,000 | $9.88 | $4,447,800.00 | -11.5% | - | - | |
| Nov 5, 2018 | ESPR Esperion Therapeutics, Inc. | 10% Owner | Sell | 100,000 | $56.38 | $5,638,342.60 | -8.3% | - | - |